Leukemia

Patients aged 75 years or older diagnosed with hematologic malignancies appear significantly underrepresented in clinical trials submitted to the U.S. Food and Drug Administration (FDA), according to a retrospective analysis.

To offset an increased risk for serious side effects, patients with chronic lymphocytic leukemia say they prefer a substantial increase in progression-free survival in order to accept this negative treatment attribute.

While recent advances in hematology are exciting, they open the door to more questions.

Sprycel (dasatinib), an oral medication that helps reduce the production of damaged white blood cells, has been approved by the Food and Drug Administration for the treatment of pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

The documentary, “Close to Home: Cancer Survivorship,” aims to educate and inspire people along their journey.

Older patients with acute myeloid leukemia (AML) often face a difficult choice: risky, intensive chemotherapy that offers a small chance of a cure versus non-intensive chemotherapy meant to improve physical comfort and quality of life.

OVER THE LAST FEW years, significant advances were made in the treatment of patients with chronic lymphocytic leukemia (CLL). Several novel therapies, most of them oral, have now been approved by the Food and Drug Administration. These include Imbruvica (ibrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor; Venclexta (venetoclax), a B-cell lymphoma-2 (BCL2) inhibitor; and Zydelig (idelalisib), a phosphoinositide 3-kinase (PI3K) inhibitor.

Venclexta (venetoclax), a BCL-2 inhibitor, had promising results in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). According to an updated analysis of a clinical trial, the agent led to negative minimal residual disease (MRD) in 40 percent of patients involved.

THERE ARE THREE STAGES of treatment for acute promyelocytic leukemia: induction therapy, consolidation therapy and maintenance therapy.

Treatment advances mean high cure rate for patients with APL.

When Gary found out that his daughter was a match to donate bone marrow to a 69-year-old man, he collapsed and cried on the streets of Santa Monica.

A novel agent is attacking a newly found target in patients with acute myeloid leukemia (AML).

The newly approved CAR T-cell therapy, Kymriah (tisagenlecleucel), is being put on the market with a price tag of $475,000 for a single infusion, which is within the range that oncologists predicted.

Kymriah, a CAR T-cell therapy, was approved to treat certain pediatric and young adult patients who have acute lymphoblastic leukemia (ALL).

Bosulif (bosutinib) was granted a priority review to a supplemental new drug application (sNDA) by the Food and Drug Administration (FDA) for use in the first-line treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML).

We can all learn some things from an extraordinary young man.

End-of-life care is of particular concern for elderly patients with AML because prognosis is poor and has not changed in several decades. Median survival for patients 65 or older is roughly two months and drops to as low as one month for patients over 85 years.

Eunice Wang, M.D., discusses a promising new drug for the treatment of certain patients with acute myeloid leukemia.

Besponsa (inotuzumab ozogamicin) was granted FDA approval for certain patients with ALL.

Driven by personal experience and his love for art, Ryan Berardi created a 3D animation that would help health care professionals if they wrongly administer chemotherapy to patients.

Vyxeos (CPX-351) was granted FDA approval for two subtypes of acute myeloid leukemia.

Idhifa (enasidenib) was granted approval by the Food and Drug Administration (FDA) today, for the treatment of patients who have relapsed or refractory IDH2-mutated acute myeloid leukemia (AML).

A recent study found that children of older parents may have an increased risk of certain types of cancers.

Blincyto (blinatumomab) was granted full approval by the Food and Drug Administration (FDA) to treat both children and adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL), regardless of Philadelphia chromosome (Ph) status, according to the developer of the anti-CD19 immunotherapy, Amgen.

Children with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia (CP Ph+ CML) may soon have a new treatment